1986
DOI: 10.1016/0002-9343(86)90164-6
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the effects of prazosin versus propranolol on plasma lipoprotein lipids in patients receiving hemodialysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

1988
1988
1994
1994

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 16 publications
(3 citation statements)
references
References 25 publications
0
3
0
Order By: Relevance
“…Plasma triglyceride levels fall in hypertensive patients (Coto et d. 1987;Swilocki et al 1989) or rats (Reaven and Ball'Aglio 1982) treated with prazosin. It has been postulated that activation of LPL (Harter et al 1986) or reduction in VLDE secretion rates (Reaven and Dal19Ag%io 1982) may occur with prazosin, which results in a decrease in VEDL and ultimately a reduction in triglyceride. However, despite the reduction in plasma triglycerides in these prmosintreated diabetic rats, there was no concomitant improvement in cardiac function.…”
Section: Discussionmentioning
confidence: 99%
“…Plasma triglyceride levels fall in hypertensive patients (Coto et d. 1987;Swilocki et al 1989) or rats (Reaven and Ball'Aglio 1982) treated with prazosin. It has been postulated that activation of LPL (Harter et al 1986) or reduction in VLDE secretion rates (Reaven and Dal19Ag%io 1982) may occur with prazosin, which results in a decrease in VEDL and ultimately a reduction in triglyceride. However, despite the reduction in plasma triglycerides in these prmosintreated diabetic rats, there was no concomitant improvement in cardiac function.…”
Section: Discussionmentioning
confidence: 99%
“…Gonen and colleagues have reported that extensive in vitro carbamylation ofLDL abolished the ability ofLDL to be recognized by the LDL receptor [64]. Indirect evidence for modification of the receptor-binding domain of LDL in uremia was given by degradation studies using cultured fibroblasts, where LDL , isolated from human uremic subjects on dialysis, was less efficient than normal LDL in competing for degradation of 125 1 LDL by fibroblasts [65]. However, no difference in the amino acid composition between normal and uremic LDL was detected.…”
Section: Metabolic Fatementioning
confidence: 99%
“…Prazosin has also been shown to induce LVH regression [13]. a-1-blockers have a major advantage over other antihypertensive agents regarding lipid metabolism: they may ameliorate the lipid profile with an increase in HDL [125,126]. Thus, even if they are not considered a first choice in ESRD arterial hypertension [89], they remain a good alternative that is well tolerated by many patients [124] and that has no biochemical side effects.…”
Section: Alpha-blockersmentioning
confidence: 99%